A systematic review of definitions of extreme phenotypes of HIV control and progression

AIDS

Volumn 28, Issue 2, 2014, Pages 149-162

  Gurdasani, Deepti ^a,b   Iles, Louise ^a,b   Dillon, David G ^a,b   Young, Elizabeth H ^a,b   Olson, Ashley D ^c   Naranbhai, Vivek ^d,e   Fidler, Sarah ^f   Gkrania Klotsas, Effrossyni ^g   Post, Frank A ^h   Kellam, Paul ^a,i   Porter, Kholoud ^c   Sandhu, Manjinder S ^a,b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Definitions; Elite controllers; Extreme trait designs; HIV; HIV controllers; Long term nonprogressors; Phenotypes; Slow progressors; Systematic review; Viremic controllers

Indexed keywords

DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MEDICAL SUBJECT HEADINGS; MEDLINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

DISEASE PROGRESSION; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; PHENOTYPE; TERMINOLOGY AS TOPIC;

EID: 84892373252     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000049     Document Type: Review

References (25)

1. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200:1714-1723.
2. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163-1169.
3. Canducci F, Marinozzi MC, Sampaolo M, Berre S, Bagnarelli P, Degano M, et al. Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology 2009; 6:4.
4. Diop G, Hirtzig T, Do H, Coulonges C, Vasilescu A, Labib T, et al. Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother 2006; 60:569-577.
5. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199:419-426.
6. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, et al. Genome-wide mRNA expression correlates of viral control in CD4R T-cells from HIV-1-infected individuals. PLoS Pathog 2010; 6:e1000781.
7. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416.
8. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Cote P, et al. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1Mh/My and HLA-BM57. J Virol 2011; 85:5949-5960.
9. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with BM57. AIDS 2002; 16:961-972.
10. Zhang Z, Jiang Y, Zhang M, Liu J, Sun G, Shi W, et al. Alterations of CD4(R) CD25(R) Foxp3(R) regulatory T cells in HIVinfected slow progressors of former blood donors in China. Microbiol Immunol 2010; 54:625-633.
11. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-1056.
12. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol 2011; 85:11422-11434.
13. Fontaine J, Coutlee F, Tremblay C, Routy JP, Poudrier J, Roger M. HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis 2009; 199:1007-1018.
14. Casado C, Colombo S, Rauch A, Martinez R, Gunthard HF, Garcia S, et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One 2010; 5:e11079.
15. Lajoie J, Fontaine J, Tremblay C, Routy JP, Poudrier J, Roger M. Persistence of high levels of blood soluble human leukocyte antigen-G is associated with rapid progression of HIV infection. AIDS 2009; 23:1437-1440.
16. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
17. Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV Med 2007; 15:134-136.
18. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009; 9:55-69.
19. Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, et al. Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis 2010; 202: 908-915.
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
21. Knapp S, Lenz P, Gerlitz S, Rieger A, Meier S, Stingl G. Highly active antiretroviral therapy responders exhibit a phenotypic lymphocyte pattern comparable to that of long-term nonprogressors. Int Arch Allergy Immunol 2001; 126:248-256.
22. Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imami N. Are long-term nonprogressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort. PLoS One 2012; 7:e29844.
23. Madec Y, Boufassa F, Avettand-Fenoel V, Hendou S, Melard A, Boucherit S, et al. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J Acquir Immune Defic Syndr 2009; 50:19-26.
24. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999; 162:6942-6946.
25. Rappaport J, Cho YY, Hendel H, Schwartz EJ, Schachter F, Zagury JF. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet 1997; 349:922-923.